Form 4: KALA BIO CEO Lazar Invests $1.8M in Preferred Stock

KALA BIO's CEO, David E. Lazar, acquired 900,000 shares of Series AA Convertible Preferred Stock for $1.8 million, with plans for a further $4.2 million investment.

Summary

• David E. Lazar, KALA BIO's Director, 10% Owner, and Chief Executive Officer, acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock.
• The acquisition occurred on November 24, 2025, at a price of $2.00 per share, totaling $1,800,000.
• Lazar also plans to acquire an additional 2,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share, for an additional $4,200,000.
• Each Series AA Preferred Stock share is convertible into 55 shares of common stock, subject to ownership limitations, potentially yielding 49,500,000 common shares.
• Each Series AAA Preferred Stock share will be convertible into 420 shares of common stock, subject to ownership limitations, potentially yielding 882,000,000 common shares.
• Conversion of both Series AA and Series AAA Preferred Stock is contingent upon stockholder approval to increase the company's authorized capital and approve the conversion in accordance with Nasdaq listing rules.

Sentiment

Score: 6

Explanation: The capital infusion from the CEO is a positive for the company's financial stability and signals insider confidence. However, the significant potential for future dilution upon conversion of the preferred stock introduces a notable negative for existing common shareholders, balancing the overall sentiment to moderately positive.

Positives

• A significant capital infusion of $1.8 million has been secured from the CEO, with an additional $4.2 million planned, totaling $6 million.
• The CEO's substantial investment signals confidence in the company's future prospects.

Negatives

• The potential conversion of preferred stock could lead to substantial dilution for existing common stockholders, with up to 931,500,000 new common shares potentially issued.
• The conversion of preferred stock is contingent on stockholder approval, introducing uncertainty regarding the full realization of the capital structure change.

Risks

• Failure to obtain stockholder approval for the increase in authorized capital and the conversion of preferred stock could prevent the preferred shares from converting into common stock.
• Significant dilution risk for current common shareholders if all preferred shares are converted, potentially impacting per-share value and voting power.

Future Outlook

The company anticipates a significant capital raise from its CEO, contingent on future stockholder approval for an increase in authorized capital and the conversion of preferred stock into common stock, which would enable the full conversion of the preferred shares.

Management Comments

• David E. Lazar, as Director, 10% Owner, and Chief Executive Officer, entered into a securities purchase agreement to acquire preferred stock, demonstrating a direct investment in the company's equity.

Industry Context

Insider investments, particularly from a CEO, can signal strong confidence in a company's prospects, especially in the biotechnology sector where capital needs are often high. However, the structure involving convertible preferred stock and the need for significant shareholder approval for conversion suggests a strategic move to secure funding while managing immediate common stock dilution, potentially indicating challenges in securing traditional equity financing.

Comparison to Industry Standards

• This transaction is an insider equity investment rather than a performance report, making direct comparisons to industry-wide financial results or project outcomes less applicable.
• While insider buying is generally viewed positively, the specific terms of this preferred stock issuance, including the high conversion ratios and the requirement for shareholder approval for significant dilution, would need to be evaluated against similar capital raises by other small-cap biotech companies to assess its favorability.

Corporate Governance

Related Party Transactions

• David E. Lazar, who is the Chief Executive Officer, a Director, and a 10% Owner of KALA BIO, Inc., acquired preferred stock from the company, constituting a related-party transaction.

Stakeholder Impact

• Shareholders face potential significant dilution of their ownership percentage and per-share value if the preferred stock is fully converted into common stock.
• The company benefits from a direct capital infusion, enhancing its financial resources for operations and strategic initiatives.
• The transaction demonstrates a strong commitment from the CEO, potentially boosting investor confidence in management's belief in the company's long-term viability.

Next Steps

• The company's stockholders must approve an increase in authorized capital to enable the issuance of common stock upon conversion of the preferred stock.
• Stockholders must also approve the conversion of the preferred stock into common stock in accordance with Nasdaq listing rules.

Key Dates

Keywords

KALA BIO, KALA, David E. Lazar, Preferred Stock, Convertible Stock, Insider Transaction, Capital Raise, SEC Form 4, CEO Investment, Dilution, Stockholder Approval, Nasdaq Listing Rules